Lisa A. de Jong

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings

Lisa A. de Jong, Jessie Groeneveld, Jelena Stevanović et al. · PLoS ONE · 2019 · 34 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15

Trends in direct oral anticoagulant (DOAC) use: health benefits and patient preference.

Lisa A. de Jong, Mike Koops, Judith J. Gout-Zwart et al. · PubMed · 2018 · 30 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands

Lisa A. de Jong, Evgeni Dvortsin, Kristel J.M. Janssen et al. · Clinical Therapeutics · 2017 · 23 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +13

Anthropometric data for magnetic resonance imaging of the carotid bifurcation

Jonathan B. Thomas, Lisa A. de Jong, J. David Spence et al. · Journal of Magnetic Resonance Imaging · 2005 · 16 citations · Full text

Medicine, Anatomy, Biomedical Imaging +9

Cost-effectiveness analysis and budget impact of rivaroxaban compared with dalteparin in patients with cancer at risk of recurrent venous thromboembolism

Lisa A. de Jong, Annette W.G. van der Velden, Marinus van Hulst et al. · BMJ Open · 2020 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17